10-Q: Oragenics Reports Q2 2026 Results, Faces Going Concern Warning

Oragenics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased operating expenses, a net loss of $2.5 million for the quarter, and continued concerns about its ability to continue as a going concern.

Summary

• Oragenics, Inc. reported its quarterly results for the period ending June 30, 2026.
• The company experienced a net loss of $2,528,707 for the three months ended June 30, 2026, compared to a net loss of $2,272,035 for the same period in 2025.
• For the six months ended June 30, 2026, the net loss was $4,729,950, an increase from $4,489,028 in the prior year.
• Research and development expenses significantly increased by 161.7% for the quarter and 130.3% for the six-month period, primarily due to costs associated with the ONP-002 concussion program.
• General and administrative expenses also saw an increase of 12.0% for the quarter, driven by higher patent-related expenses.
• The company's cash and cash equivalents stood at $3,864,184 as of June 30, 2026, and management believes this is sufficient to fund operations through the end of 2026.
• However, the report reiterates substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant operating losses, a substantial accumulated deficit, and an ongoing going concern warning, despite progress in clinical trials.

Positives

• Zero serious adverse events have been reported in the ongoing Phase IIa clinical trial for ONP-002.
• The company submitted a Type B Meeting request to the FDA in July 2026 to discuss the ONP-002 clinical development program.
• The company's cash and cash equivalents of $3.9 million are believed to be sufficient to fund planned operations through the end of 2026.
• Interest income increased by 78.80% for the three months ended June 30, 2026, compared to the prior year period, due to higher average cash and investment balances.

Negatives

• Net loss for the three months ended June 30, 2026, was $2,528,707, an increase of 11.30% from the prior year.
• Net loss for the six months ended June 30, 2026, was $4,729,950, an increase of 5.37% from the prior year.
• Research and development expenses increased by 161.7% for the quarter and 130.3% for the six-month period.
• General and administrative expenses increased by 12.0% for the quarter.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company has an accumulated deficit of $231.4 million as of June 30, 2026.
• The company paused discussions with Sigyn Therapeutics regarding a potential license for CardioDialysis technology.

Risks

• The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.
• Additional capital will be required to complete development and commercialization of product candidates, and there is no assurance that such financing will be obtained on acceptable terms.
• The anti-dilution provisions in the Series H Preferred Stock could lead to a greater number of shares being issued upon conversion, resulting in significant dilution to existing shareholders.
• The market price of common stock may never exceed the conversion price of the Series H Preferred Stock, potentially leading to unexercised warrants.
• Future sales of common stock in the public market could cause the stock price to fall.
• The company may not be successful in acquiring, investing in, or integrating businesses, or entering into joint ventures.
• The company may not be able to successfully consummate the transaction contemplated by the Sigyn Letter of Intent.
• The company is involved in a legal proceeding concerning a Bill of Discovery related to its purchase of assets from Odyssey.

Future Outlook

The company expects to incur substantial expenditures to advance its neurology assets, including ONP-002, through clinical trials and potential commercialization. Additional capital will be required to fund planned clinical trials, regulatory filings, and future commercialization efforts. Management believes current capital is sufficient to fund operations through the end of 2026, but additional financing is anticipated.

Management Comments

• "Subject to our ability to raise additional capital, of which there can be no assurances, we expect to continue to incur substantial expenses as we advance the development of ONP-002, our lead product candidate for the treatment of mild traumatic brain injury and explore potential acquisitions."
• "We view these business development activities as a necessary component of our strategies, and we seek to enhance shareholder value by evaluating business development opportunities both within and complementary to our current business, as well as opportunities that may be new and separate from the development of our existing product candidates."
• "As of the date hereof, we are not actively negotiating such license agreement or undertaking any further due diligence regarding CardioDialysis and have paused discussions with Sigyn, choosing instead to continue to focus on ONP-002 and our capital raising efforts."
• "There can be no assurance that we will be able to obtain such financing on acceptable terms, or at all."

Industry Context

StockSavvy.ai notes that Oragenics operates in the highly competitive and capital-intensive biopharmaceutical sector, where success is heavily reliant on clinical trial outcomes and securing substantial funding for drug development. The focus on a novel treatment for mild traumatic brain injury addresses a significant unmet medical need, but the path to regulatory approval and commercialization is long and fraught with risk.

Comparison to Industry Standards

• The company's R&D spending as a percentage of total operating expenses for the six months ended June 30, 2026, was approximately 37.6% ($1.8M / $4.8M), which is typical for a development-stage biopharmaceutical company focused on a lead candidate.
• The significant increase in R&D expenses (130.3%) aligns with the progression of ONP-002 into Phase IIa trials and preparation for U.S. trials, a common expenditure pattern for companies advancing drug candidates.
• The company's net loss of $4.7 million for the first six months of 2026 is consistent with many pre-revenue biopharmaceutical companies that are investing heavily in research and development.
• The ongoing 'going concern' warning is a prevalent risk for many early-stage biotechs that have not yet achieved profitability or secured long-term funding.

Management Changes

Legal Proceedings

• Jacob Vanlandingham filed a Complaint for a Pure Bill of Discovery on April 24, 2026, seeking discovery related to the Company's purchase of assets from Odyssey. The Company is contesting this matter.

Stakeholder Impact

• Shareholders may experience significant dilution due to potential future equity issuances and the anti-dilution provisions of Series H Preferred Stock.
• The ongoing going concern warning poses a risk to the company's long-term viability, impacting all stakeholders.
• Successful development of ONP-002 could significantly benefit patients suffering from mild traumatic brain injury.
• Employees may face uncertainty due to the company's financial position and the need for future capital raises.

Next Steps

• Advance ONP-002 toward Phase II clinical trials.
• Conduct IND-enabling activities to support U.S. based clinical trials.
• Scale manufacturing of clinical trial material for ONP-002.
• Continue to focus on capital raising efforts.
• Pursue strategic partnerships, acquisitions, and licensing arrangements.

Key Dates

Recommendation

The company is in a critical development stage with a promising lead candidate (ONP-002) for a significant unmet need. However, the substantial operating losses, accumulated deficit, and explicit going concern warning necessitate caution. While clinical trial progress is positive, the company's ability to secure necessary future funding is paramount and carries significant risk. A 'hold' recommendation reflects the speculative nature of the investment, balancing potential upside with considerable downside risk.

Keywords

Oragenics, ONP-002, mild traumatic brain injury, concussion, clinical trials, biopharmaceutical, Form 10-Q, FDA